(ARRY) Setback for Array BioPharma’s Drug
Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better...
View Article(GILD) Top Franklin Templeton Funds – Mutual Fund Education
Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms. This non-diversified fund may invest...
View Article(ONXX) Onyx Pharmaceuticals to Acquire Cancer Drugmaker Proteolix
Recently, Onyx Pharmaceuticals (ONXX) announced that it will purchase privately held cancer drugmaker Proteolix for an upfront cash payment of $276 million. This transaction gives Onyx access to...
View Article(GILD) Top Franklin Templeton Funds – Mutual Fund Education
Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms. This non-diversified fund may invest...
View Article(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from...
by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make...
View Article(CYTR) Good News for CytRx Corporation
CytRx Corp. (CYTR) announced that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on its molecular chaperone candidate arimoclomol for treating patients suffering from amyotrophic...
View Article(CELG) Celgene Corporation to Expand
Celgene Corporation (CELG) recently announced that it will purchase the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The...
View Article(ONXX) Onyx Pharmaceuticals gets Positive Data
Recently, Onyx Pharmaceuticals (ONXX) came out with positive data from a phase IIb study of carfilzomib at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans. We are...
View Article(CELG) Celgene Corporation Presents Revlimid Data
Celgene Corporation (CELG) announced recently that its cancer drug Revlimid reduced the risk of progression of the disease in newly diagnosed patients with multiple myeloma (MM) by 50%. The data was...
View Article(CELG) Celgene Drug Meets Study Goal
Celgene Corp. (CELG) recently disclosed that its drug candidate, apremilast, for treating patients with moderate-to-severe plaque-type psoriasis, met key goals in a mid-stage study (n=352). The...
View Article(CELG) Celgene Corporation Scores with Revlimid
Celgene Corporation (CELG) announced recently that initial results from a late-stage study in multiple myeloma (MM) patients revealed that those treated with Revlimid underwent a 58% reduction in...
View Article(CELG) Preliminary Earnings Results from Celgene
Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks...
View Article($JPM) JP Morgan Healthcare Conference in San Francisco
by Marc Lichtenfeld, Healthcare Expert Wednesday, January 13, 2010: Issue #1174 Cautiously optimistic. Very cautiously optimistic. That’s how I’d describe the overall mood at this year’s JP Morgan...
View Article(CELG) Celgene Corporation Announces Good News for Cancer Drug Study
Yesterday, Celgene Corporation (CELG) announced that its cancer drug Revlimid met the main goal in a randomized, double-blind, multi-center late-stage study (IFM 2005 02). The study, sponsored by the...
View Article(CELG) Celgene Corporation Expands into Cancer Drugs
Recently, Celgene Corporation (CELG) completed the acquisition of the privately held Gloucester Pharmaceuticals for $340 million in cash coupled with $300 million in future milestone payments. The deal...
View Article(CELG) Celgene Reports Earnings Ahead of Estimates
This morning, Celgene Corp. (CELG) reported fourth quarter and full year results for fiscal 2009. Quarterly Results The company earned 62 cents per share in the fourth quarter as opposed to 43 cents in...
View Article(ARRY) Array BioPharma and Novartis AG Sign Deal for Treating Cancer
Recently, Array BioPharma Inc. (ARRY) struck a deal with Novartis AG (NVS) to develop its small-molecule methyl ethyl ketone (MEK) inhibitors for treating cancer. The transaction is worth up to $467...
View Article(GIS) Company News for June 30, 2010 – Corporate Summary
• General Mills (NYSE:GIS) raised its dividend before reporting inline fiscal fourth-quarter earnings of 41 cents a share, but its guidance for fiscal 2011 came in below Street expectations. Revenues...
View Article(ABT) Pharma and Biotech Industry Outlook – July 2010 – Industry Outlook
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and...
View Article(ABT) Pharma and Biotech Industry Outlook – July 2010 – Analyst Interviews
The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and...
View Article(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the...
View Article(MRK) Pharma Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the...
View Article(CELG) Celgene Analyst Maintains Neutral Recommendation
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
View Article(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development...
View Article(CELG) Celgene Buys Abraxis BioSciences for $2.9 Billion
The spate of acquisitions in the pharmaceutical industry continued with Celgene Corporation (CELG) completing the purchase of Abraxis BioScience Inc. for $2.9 billion in cash and stock. Celgene aims to...
View Article(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited...
View Article(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage...
View Article(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry....
View Article(CELG) Celgene Corporation Wins Label Expansion for Istodax
Recently, the US Food and Drug Administration (FDA) delivered a boost to Celgene Corporation (CELG) by approving its cancer drug Istodax (romidepsin) for an additional indication. The US regulatory...
View Article(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even...
View Article(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage...
View Article(CELG) Celgene Corporation – Bull of the Day
We are upgrading Celgene Corporation (CELG) to Outperform from Neutral following strong second quarter results delivered by the company and the decision of CHMP that the benefits associated with...
View Article(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and...
View Article(CELG) Celgene Corporation – Bull of the Day
We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS...
View Article(ISRG) Now is the Time to Buy Healthcare Stocks
I’ve been talking a lot lately about the $4 trillion that’s about to fall into the laps of businesses in the healthcare sector due to the number of Baby Boomers who are now turning 65. And we know that...
View Article(ARE) Alexandria Real Estate Equities Sees New Lease Agreements
Alexandria Real Estate Equities, Inc. (ARE), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a...
View Article(PFE) Pharma and Biotech Stock Outlook – August 2012 – Industry Outlook
The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November...
View Article(MRK) Pharmaceuticals and Biotech Stock Outlook – December 2012 – Industry...
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair,...
View Article(AAPL) Fourth Quarter 2012 Earnings Season Gets Into High Gear – Earnings...
The fourth quarter reporting season gets into high gear this week, with 253 companies coming out with quarterly results, including 83 S&P 500 companies. The earnings season thus far has been...
View Article(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews
We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost...
View Article(AMGN) The Picks and Shovels (and Levi’s) of Biotech
Yesterday marked the 184th birthday of an iconic American businessman – Levi Strauss My wife worked for Levi Strauss & Co. many years ago. They were a terrific company, with a strong commitment to...
View Article(CELG) Celgene Plans $600M Share Buyback
Celgene Corporation (CELG) recently entered into an accelerated share repurchase (ASR) agreement with an investment bank. The agreement will allow Celgene to repurchase around $600 million of its...
View Article(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews
The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...
View Article(REGN) Regeneron Pharmaceuticals Rated Neutral Again
We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron Pharmaceuticals (REGN). Our target price is $195.00 per share. Why the Reiteration? Regeneron reported...
View Article(NVS) Theravance – Glaxo Drug to Face FDA Panel
The US Food and Drug Administration (FDA) recently released briefing documents ahead of the review by its Pulmonary-Allergy Drugs Advisory Committee of the New Drug Application (NDA) of...
View Article(ENDP) Endo Health Solutions Sees FDA Setback on Opana ER
Endo Health Solutions Inc. (ENDP) recently suffered a setback with the US Food and Drug Administration (FDA) turning down its request to prevent the entry of generic versions of the company’s...
View Article(BMY) Bristol-Myers Squibb Company Earns Good News From FDA
Bristol-Myers Squibb Company (BMY) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major’s HIV drug Sustiva for...
View Article(GILD) Gilead’s Sofosbuvir under European Review
Gilead Sciences Inc. (GILD) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European Medicines Agency (EMA) on...
View Article(NPSP) NPS Pharmaceuticals Prices Offering
NPS Pharmaceuticals, Inc. (NPSP) recently priced a public offering of 6,000,000 shares at $14.53 a share, with a 30-day over-allotment option for an additional 900,000 shares. NPS Pharma expects to...
View Article(PPHM) Peregrine Pharmaceuticals Shows Encouraging News
Peregrine Pharmaceuticals (PPHM) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration...
View Article
